Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Baclofen and Botulinum Toxin on NFR Threshold in Spastic Hemiplegia
NCT03860662Phase 4Completed
- Sponsor
- Hatay Mustafa Kemal University
- Start
- May 2018
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of botulinum toxin type A and baclofen in spastic hemiplegia (2 arms), sponsored by Hatay Mustafa Kemal University. Primary endpoints: Threshold of nociceptive flexor reflex at 6 weeks, Barthel daily life activities index at 6 weeks and 3 more. Started May 2018; status: completed.
02
Drugs
botulinum toxin type Abaclofen
03
Conditions
spastic hemiplegia
Beyond the preview
Go deeper on NCT03860662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860662.